Physician profile
Matthew Hasley
NPI 1023457454
$2,587.68
in general payments reported to CMS, 2019-2025
31 companies · $628 in 2025
The $628 reported for 2025 was more than what 82% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $140 · 2021: $196 · 2022: $419 · 2023: $597 · 2024: $337 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,105.26 | 2022-2025 | |
| Allergan, INC. | $219.05 | 2019-2022 | |
| Silk Road Medical, INC. | $159.38 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Merz Pharmaceuticals, LLC | $142.24 | 2022-2025 | Xeomin, Ampyra, Inbrija |
| Abbott Laboratories | $109.40 | 2019-2025 | Eterna |
| Depuy Synthes Sales INC. | $90.13 | 2022-2023 | Matrixneuro, Synthecel |
| Medtronic, INC. | $78.18 | 2021-2024 | Synchromedii |
| Medtronic USA, INC. | $58.17 | 2019-2020 | |
| Baxter Healthcare | $58.10 | 2019-2021 | |
| Ossur Americas, INC. | $53.29 | 2025 | |
| Pacira Therapeutics, INC. | $50.67 | 2020 | |
| Boston Scientific Corporation | $45.78 | 2023-2025 | Clinical Trial Product |
| Nevro Corp. | $37.45 | 2021 | |
| Philips North America LLC | $32.45 | 2019 | |
| Si-Bone, INC. | $29.54 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lemaitre Vascular, INC. | $29.03 | 2022-2025 | Anastoclip Gc 8cm (Medium) |
| Bioventus LLC | $28.91 | 2022 | |
| Novocure INC. | $26.94 | 2019 | |
| Radius Health, INC. | $26.08 | 2025 | Tymlos |
| Collegium Pharmaceutical, INC. | $22.75 | 2023 | Xtampza |
| Kls-Martin L.P. | $22.50 | 2023 | |
| Azurity Pharmaceuticals, INC. | $22.22 | 2023 | Gliadel |
| Amgen INC. | $21.22 | 2025 | Uplizna |
| Csl Behring | $19.07 | 2019 | |
| Penumbra, INC. | $18.72 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.10 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.75 | 2022 | |
| Portola Pharmaceuticals, LLC | $13.65 | 2019 | |
| Flowonix Medical Incorporated | $12.77 | 2019 | |
| Pfizer INC. | $12.49 | 2019 | |
| Stimwave Technologies Incorporated | $11.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Hasley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.